

26 JANUARY 2015 - 5.45 PM CET

CARDIO3 BIOSCIENCES ANNOUNCES AGENDA AND WEBCAST FOR 2015 NYC INVESTOR DAY

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the discovery and development of cell therapies, today announces agenda and webcast details for its 2015 Investor & Analyst Day being held Friday, January 30 in New York, NY from 8:00 a.m. – 12:00 p.m. ET.

The agenda will include:

Introduction & Welcome	Dr. Christian Homsy , Chief Executive Officer, C3BS
Regenerative Medicine for Cardiac Indications	Dr. André Terzic , Director, Center for Regenerative Medicine, Mayo Clinic Dr. Atta Behfar , Assistant Professor of Medicine and Senior Associate Consultant, Division of Cardiovascular Diseases, Mayo Clinic Dr. Jozef Bartunek , Associate Director, Cardiovascular Centre, Aalst Belgium Dr. Thomas Povsic , Associate Professor of Medicine and Interventional Heart Specialist, Duke Medicine Dr. Amit Patel , Director of Cardiovascular Regenerative Medicine, University of Utah School of Medicine Division of Cardiothoracic Surgery Dr. Warren Sherman , Chief Medical Officer, Cardio3 Biosciences
Immunotherapy & CAR T-Cell Technology	Dr. Ivan Borrello , Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine Dr. Charles Sentman , Professor of Microbiology and Immunology and Director, Center for Synthetic Immunity, Geisel School of Medicine, Dartmouth College Dr. Susanne Baumeister , Attending Physician, Hematology & Oncology, Dana-Farber Cancer Institute Dr. David Ghilham , Clinical and Experimental Immunotherapy Group, Institute of Cancer Sciences, University of Manchester, United Kingdom Dr. Vincent Brichard , VP Immuno-Oncology, Cardio3 Biosciences
C3BS' Financial Strategy	Patrick Jeanmart , Chief Financial Officer, C3BS
Closing Remarks	Michel Lussier , Chairman of the Board, C3BS

Following the event, an archived audio webcast with slide presentation will be available by visiting the Events section of Cardio3's website at <http://www.c3bs.com/en/events>. The webcast will be available on the Cardio3 website for one year.

Attendance at The Cardio3 BioSciences Analyst Day is by invitation only.

To request an invitation for the event, please contact Taylor Donovan of The Ruth Group at tdonovan@theruthgroup.com or +1 646-536-7017.

*** END ***



26 JANUARY 2015 - 5.45 PM CET

For more information, please contact:

Cardio3 BioSciences

Christian Homys, CEO

Julie Grade, Corporate Communications Manager

For Europe: Consilium Strategic Communications

Amber Bielecka, Chris Welsh, Laura Thornton

For the U.S: The Ruth Group

Lee Roth (Investors), Kirsten Thomas (Media)

www.c3bs.com

Tel: +32 10 39 41 00

jgrade@c3bs.com

Tel : +44 20 3709 5700

cardio3@consilium-comms.com

Tel: +1 646 536 7012 / 7014

lroth@theruthgroup.com

kthomas@theruthgroup.com

To subscribe to Cardio3 BioSciences' newsletter, visit www.c3bs.com.

 Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

About Cardio3 BioSciences

Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of cell therapies for the treatment of unmet medical needs in cardiology and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA and in Europe with the Mayo Clinic (MN, USA) and Dartmouth College (NH, USA). The Company's lead product candidate in cardiology is C-Cure[®], an autologous stem cell therapeutic using guided stem cells for the condition of congestive heart failure. The Company's lead product candidate in oncology is CM-CS1, an autologous CAR T-Cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including hematologic cancers and solid tumors. Cardio3 BioSciences is also developing a portfolio of medical devices for enhancing the delivery of bio therapeutic agents into the myocardium (C-Cath_{ez}[®]) and for cardiac surgery involving mitral valve defects.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

To learn more about Cardio3 BioSciences, please visit www.c3bs.com

C3BS-CQR-1, C-Cure, CM-CS1, C-Cath_{ez}, OnCyte, Cardio3 BioSciences and the Cardio3 BioSciences, C-Cath_{ez}, CHART-1, CHART-2 and OnCyte logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.